Drug Trial Radar · NCT04424316
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14,727
Actual
Start
Jun 17, 2020
Primary completion
Oct 27, 2023
Study completion Oct 27, 2023
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 0 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.
Conditions
- Respiratory Tract Infection
Interventions
RSVpreFBiological
RSV vaccine (RSVpreF)
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Infant Participants With Medically Attended Lower Respiratory Tract Illness (MA-LRTI) Cases Due to RSV Occurring Within 90 Days After Birth (Efficacy)Time frame: Within 90 days after birth
- Percentage of Infant Participants With MA-LRTI Cases Due to RSV Occurring Within 120 Days After Birth (Efficacy)Time frame: Within 120 days after birth
- Percentage of Infant Participants With MA-LRTI Cases Due to RSV Occurring Within 150 Days After Birth (Efficacy)Time frame: Within 150 days after birth
- Percentage of Infant Participants With MA-LRTI Cases Due to RSV Occurring Within 180 Days After Birth (Efficacy)Time frame: Within 180 days after birth
- Percentage of Infant Participants With Severe MA-LRTI Cases Due to RSV Occurring Within 90 Days After Birth (Efficacy)Time frame: Within 90 days after birth
- Percentage of Infant Participants With Severe MA-LRTI Cases Due to RSV Occurring Within 120 Days After Birth (Efficacy)Time frame: Within 120 days after birth
- Percentage of Infant Participants With Severe MA-LRTI Cases Due to RSV Occurring Within 150 Days After Birth (Efficacy)Time frame: Within 150 days after birth
- Percentage of Infant Participants With Severe MA-LRTI Cases Due to RSV Occurring Within 180 Days After Birth (Efficacy)Time frame: Within 180 days after birth
- Percentage of Infant Participants With Adverse Events of Special Interest (AESI) (Safety)Time frame: From birth to 24 months of age
- Percentage of Infant Participants With Neonatal Deaths (Safety)Time frame: Within 1 Month after birth
- Percentage of Infant Participants With Congenital Malformations/Anomalies (Safety)Time frame: At birth
- Percentage of Infant Participants With Other Neonatal Events (Safety)Time frame: Within 1 Month after birth
- Number of Infant Participants According to Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 Minute After Birth (Safety)Time frame: 1 minute after birth
- Number of Infant Participants According to APGAR Score at 5 Minutes After Birth (Safety)Time frame: 5 minutes after birth
- Number of Infant Participants According to APGAR Score at 10 Minutes After Birth (Safety)Time frame: 10 minutes after birth
- Percentage of Infant Participants With Adverse Events (AEs) From Birth to 1 Month of Age (Safety)Time frame: From birth to 1 month of age
- Percentage of Infant Participants With Serious Adverse Events (SAEs) and Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Birth Through 6 Months of Age (Safety)Time frame: From birth to 6 months of age
- Percentage of Infant Participants With SAEs and NDCMCs From Birth Through 12 Months of Age (Safety)Time frame: From birth to 12 months of age
- Percentage of Infant Participants With SAEs and NDCMCs From Birth Through 24 Months of Age (Safety)Time frame: From birth to 24 months of age
- Percentage of Maternal Participants With Prespecified Local Reactions Within 7 Days After Vaccination (Safety)Time frame: From Day 1 to Day 7 after vaccination
- Percentage of Maternal Participants With Prespecified Systemic Events Within 7 Days After Vaccination (Safety)Time frame: From Day 1 to Day 7 after vaccination
- Percentage of Maternal Participants With AEs From the Time of Vaccination Through 1 Month After Vaccination (Safety)Time frame: From vaccination on Day 1 up to 1 month after vaccination
- Percentage of Maternal Participants With SAEs Throughout the Study Period (Safety)Time frame: From vaccination on Day 1 up to 6 months after delivery (maximum up to 10 months)
Locations
464 sites in 18 countries. Site status is shown where the registry gives one.
Central Research Associates, Inc.
Birmingham, Alabama
Endocrinology and Internal Medicine Associates, PC
Birmingham, Alabama
OB/GYN Associates of Alabama, PC
Birmingham, Alabama
Sharp and Stone OB/GYN PC
Birmingham, Alabama
St Vincent's Hospital
Birmingham, Alabama
Children's of Alabama
Birmingham, Alabama
UAB Women & Infants Center - UAB Medicine
Birmingham, Alabama
University of Alabama at Birmingham/Center for Women's Reproductive Health
Birmingham, Alabama
Cullman Clinical Research, Inc
Cullman, Alabama
Cullman Primary Care, PC
Cullman, Alabama
Cullman Regional
Cullman, Alabama
University of South Alabama Children's and Women's Hospital
Mobile, Alabama
USA Health Strada Patient Care Center
Mobile, Alabama
Springhill Medical Center
Mobile, Alabama
Velocity Clinical Research, Gulfport
Mobile, Alabama
Velocity Clinical Research - Pheonix
Phoenix, Arizona
Valleywise Comprehensive Health Center Women's Clinic
Phoenix, Arizona
Valleywise Health Medical Center
Phoenix, Arizona
Mesquite Pediatrics
Tucson, Arizona
Watching Over Mothers and Babies
Tucson, Arizona
Banner University Medical Center
Tucson, Arizona
University of Arizona
Tucson, Arizona
Banner University Medical Center ( North Campus )
Tucson, Arizona
St. Bernards Medical Center
Jonesboro, Arkansas
St. Bernards OBGYN Associates
Jonesboro, Arkansas
The Children's Clinic of Jonesboro, P.A.
Jonesboro, Arkansas
The Children's Clinic of Jonesboro, PA
Jonesboro, Arkansas
Century Research Institute
Bellflower, California
Chowchilla Medical Center
Chowchilla, California
Loma Linda University Pediatric Clinic - Highland
Highland, California
Century Research Institute
Huntington Park, California
Matrix Clinical Research
Huntington Park, California
Chemidox Clinical Trials
Lancaster, California
Leonard S. Kurian, M.D., A Medical Corporation
Lancaster, California
Women & Infants Pavilion, Antelope Valley Hospital
Lancaster, California
Loma Linda University Adventist Health Sciences Center
Loma Linda, California
Loma Linda University Faculty Medical Clinics
Loma Linda, California
Loma Linda University Pediatric Clinics
Loma Linda, California
Loma Linda Unversity Children's Hospital
Loma Linda, California
Long Beach Clinical Trials
Long Beach, California
Showing 40 of 464 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.